EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) changes shares on Tuesday trading session, with a change of 3.41% or $0.02 shares. The trading starts at $0.73 and closed at $0.71 throughout the day. The trading session low price was $0.7101 and day high was $0.739 on Tuesday, August 04. After the session, the Healthcare sector daily volume shifted to 0.62 million while its average volume is 871.68K. In other hand, the EYPT market cap reached to $93.65M.
On June 17, 2020, BRIEF-Eyepoint Pharmaceuticals Got Letter From Nasdaq As Co Didn’t Meet Minimum Price For Continued Listing – SEC Filing. According to the news reported on Reuters, * EYEPOINT PHARMACEUTICALS – GOT LETTER FROM NASDAQ CO DIDN’T MEET MINIMUM PRICE FOR CONTINUED LISTING – SEC FILING Source text: https://bit.ly/2URUIKa Further company coverage:
Checking out the performance report which defines the increase or decrease of prices for a specific period. For the last 5 trading sessions, its performance is down -0.87% and up 1.37% for month. Its quarterly performance was -18.47% below, while its half year performance is down -62.38%. EYPT yearly performance stood at negative -41.14% and fall -52.91% for year-to-date. Current recommendation for EyePoint Pharmaceuticals Inc. is 2.20.
Earnings per share or EPS is an important financial measure, which defines the profitability of a company. EYPT EPS (TTM) for 12-month is -0.47. EPS for this year is -3.60%, while for the next year its value is 0.12. Its EPS Q/Q reached 43.40%. It has an EPS of -35.80% down for past five years.
Let’s take a look on the analyst recommendations on EYPT for the current month and previous month. For the current month, 2 of 4 analysts recommend stock as Buy while 0 as Sell, 0 as overweight, 0 as underweight and 2 as Hold. As compared with the previous month ratings, 4 analysts participate in stock recommendation. Out of 4, 0 rated it sell, 3 rated it as Buy and 1 as Hold Ratings. On the other hand, target price ranges from $1.00 – $5.00. Average target price for EYPT was reached at $3.33.
Essex Woodlands Management Inc., HighTower Advisors, LLC and Blackrock Inc. are the top three holders in EyePoint Pharmaceuticals Inc. (EYPT) stock. On Mar 30, 2020, Essex Woodlands Management Inc. has 41.91 million shares which valued 42.75 million. On Mar 30, 2020, HighTower Advisors, LLC owned 5.28 million shares which valued at 5.39 million. On Mar 30, 2020, Blackrock Inc. has a total of 5.07 million shares which valued at 5.17 million. In the end, Blackrock Inc. have 4.06% shares outstanding of EyePoint Pharmaceuticals Inc. (EYPT) on Mar 30, 2020. The insider ownership moved to 0.70% and institutional holding shifted to 54.20%.
The company posted an EPS (TTM) of -0.47. According to the most recent quarter report on (Jun 2020), 4 analysts estimated an average EPS of -0.1, while -0.11 EPS posted a year ago period. Analyst Estimated EPS for EYPT published in the report was -$0.12 – -$0.09 during the same period. Comparing with last year, the average estimated EPS was -0.11 which is equal to -0.11 which was posted for recent quarter EPS.
A brief look on simple moving average (SMA) that determines the market price can impact a market. The SMA for EYPT fall -42.19% for period of 200 days. SMA for 50 days was -7.55% which is showing red signal, while SMA-20 was 0.43%. The moving average value for EyePoint Pharmaceuticals Inc. (EYPT) is 4.5M and 1.75% for 200 and 50 days respectively.
Let’s take a look on the insider transactions, in which multiple shareholders are showing interest in EYPT stock. On Mar 12, Elston George, Chief Financial Officer, bought 10,000 trading shares at the cost of $0.96, which valued at 9600.0. On Mar 10, Lurker Nancy, President & CEO, bought 98,000 shares at the cost of $1.06, with total shares of 574,800. On Nov 15, Elston George, Chief Financial Officer, bought 10,000 shares at the cost of 1.43. After this transaction, Elston George total shares reached to 10,000 which valued at 14290.0.